Drugs / OBEROTATUG RAVTANSINE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05930951 | Nov 2023 → Oct 2024 | adenoid cystic carcinoma | Groupe Oncologie Radiotherapie Tete et Cou | Terminated | No outcome recorded |
| Phase 1 | NCT04064359 | Jul 2019 → Dec 2026 expected | cancer | Oxford BioTherapeutics Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT03403725 | Aug 2017 → Oct 2019 | metastatic neoplasm, non-Hodgkin lymphoma | Menarini Group | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2022-05-27 | Oxford BioTherapeutics Ltd | Results Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022 oxfordbiotherapeutics.com ↗ |
| 2022-04-07 | Oxford BioTherapeutics Ltd | Results AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combination with Checkpoint Inhibitors for Experimental ADC Medicine OBT076 oxfordbiotherapeutics.com ↗
Initial data from the Phase 1 dose escalation part of the OBT076 trial in adult patients with advanced solid tumors indicated that OBT076 had a favorable tolerability profile ; recommended dose was defined at 3.0 mg/kg |
| 2019-06-28 | Menarini Group | Results Menarini Ricerche announces publication of pre-clinical data of the first-in-class antibody-drug conjugate MEN1309/OBT076, currently in Phase I clinical development menarini.com ↗
The study showed that CD205, a transmembrane glycoprotein, is robustly expressed in a variety of solid malignancies, such as pancreatic and bladder tumors, as well as triple negative breast cancer (TNBC). |
| 2018-12-21 | Oxford BioTherapeutics Ltd | Regulatory Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076: An Experimental First in Class ADC Medicine for High Risk Her2 Negative Breast Cancer, Gastric, Lung, Bladder and Ovarian Cancer Patients oxfordbiotherapeutics.com ↗
Oxford BioTherapeutics receives US FDA IND Clearance for OBT076 |
| 2017-06-21 | Menarini Group | Results Menarini Ricerche to present the most recent data about the pre-clinical development of its novel ADC MEN1309/OBT076 at the 29th Pezcoller Symposium menarini.com ↗
Indeed, MEN1309/OBT076 showed impressive anti-tumoral activity against NHL and triple negative breast cancer cell lines, in the corresponding xenograft models and in Patient-Derived Xenograft (PDX) models. |
All press releases naming this drug 12 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OBEROTATUG RAVTANSINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314757 ↗ |
| Known as | MEN1309 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03403725 ↗ |
| Known as | Oberotatug ravtansina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314757 ↗ |
| Known as | OBT076 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05930951 ↗ |
| Action | Deplete | “OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them.” NCT04064359 ↗ |
| Modality | Other / unclassified | “CD205 Antibody-Drug Conjugate” NCT03403725 ↗ |
| Route | Intravenous | “intravenous infusion” NCT03403725 ↗ |
| Target | LY75 | “antibody directed against the CD205/Ly75 antigen (MBH1309)” NCT05930951 ↗ |